Madeleine Heroux
Montreal, QC H3C3J7, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
From Lead to Clinical Candidate: Discovery of BMS-986331 as a Potent and Selective N-Formyl Peptide Receptor 2 Agonist.
Journal: Journal of medicinal chemistry
Published: February 17, 2026
Conformation- and activation-based BRET sensors differentially report on GPCR-G protein coupling.
Journal: Science signaling
Published: June 18, 2024
Molecular Mechanisms of Desensitization Underlying the Differential Effects of Formyl Peptide Receptor 2 Agonists on Cardiac Structure-Function Post Myocardial Infarction.
Journal: ACS pharmacology & translational science
Published: March 08, 2022
Effector membrane translocation biosensors reveal G protein and βarrestin coupling profiles of 100 therapeutically relevant GPCRs.
Journal: eLife
Published: September 21, 2021
BRET-based effector membrane translocation assay monitors GPCR-promoted and endocytosis-mediated Gq activation at early endosomes.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: May 15, 2021
Selective FPR2 Agonism Promotes a Proresolution Macrophage Phenotype and Improves Cardiac Structure-Function Post Myocardial Infarction.
Journal: JACC. Basic to translational science
Published: March 30, 2021
In Vitro and In Vivo Evaluation of a Small-Molecule APJ (Apelin Receptor) Agonist, BMS-986224, as a Potential Treatment for Heart Failure.
Journal: Circulation. Heart failure
Published: March 05, 2021
Preservation of Post-Infarction Cardiac Structure and Function via Long-Term Oral Formyl Peptide Receptor Agonist Treatment.
Journal: JACC. Basic to translational science
Published: February 22, 2019
Tetrahydroisoquinoline CXCR4 Antagonists Adopt a Hybrid Binding Mode within the Peptide Subpocket of the CXCR4 Receptor.
Journal: ACS medicinal chemistry letters
Published: September 24, 2018
Showing 1-9 of 9
Last Updated: 09/26/2026